Company Description
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient’s body.
Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
The company is also developing CUE-102 targets Wilms’ Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series.
It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine.
The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016.
Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | Jan 2, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 53 |
| CEO | Daniel R. Passeri J.D., M.Sc. |
Contact Details
Address: 40 Guest Street Boston, Massachusetts 02135 United States | |
| Phone | 617-949-2680 |
| Website | cuebiopharma.com |
Stock Details
| Ticker Symbol | CUE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001645460 |
| CUSIP Number | 22978P106 |
| ISIN Number | US22978P1066 |
| Employer ID | 47-3324577 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel R. Passeri J.D., M.Sc. | Chief Executive Officer and Director |
| Dr. Anish Suri Ph.D. | President and Chief Scientific Officer |
| Kerri-Ann Millar | Chief Financial Officer |
| Dr. Ronald D. Seidel III, Ph.D. | Co-Founder |
| Dr. Rodolfo J. Chaparro | Co-Founder and Senior Advisor |
| Dr. Steven C. Almo | Co-Founder and Chairman of Scientific and Clinical Advisory Board |
| George B. Zavoico Ph.D. | Vice President of Investor Relations and Corporate Development |
| Colin G. Sandercock J.D., MSE | Senior Vice President, General Counsel and Secretary |
| Dr. Matteo Levisetti M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 7, 2024 | 8-K | Current Report |
| May 24, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 9, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | ARS | Filing |
| Mar 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 11, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |